These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2229131)

  • 21. Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines.
    Du YH; Ho PC
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):481-90. PubMed ID: 11459200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
    Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
    Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
    Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
    Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II).
    Husain A; Rosales N; Schwartz GK; Spriggs DR
    Gynecol Oncol; 1998 Jul; 70(1):17-22. PubMed ID: 9698467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response.
    Nakada S; Aoki D; Ohie S; Horiuchi M; Suzuki N; Kanasugi M; Susumu N; Udagawa Y; Nozawa S
    Int J Gynecol Cancer; 2005; 15(3):445-52. PubMed ID: 15882168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of pentoxifylline, A-802710, propentofylline and A-802715 (Hoechst) on the expression of cell cycle blocks and S-phase content after irradiation damage.
    Bohm L; Theron T; Binder A
    Biochim Biophys Acta; 2000 Dec; 1499(1-2):1-10. PubMed ID: 11118634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic therapy can inhibit growth of ovarian cancer cells and reverse chemoresistant properties acquired from metastatic omentum.
    Sookram J; Zheng A; Linden KM; Morgan AB; Brown SA; Ostrovsky O
    Int J Gynaecol Obstet; 2019 May; 145(2):225-232. PubMed ID: 30828803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of extracellular ATP on cisplatin-induced cytotoxicity in human ovarian carcinoma cells.
    Rotte A; Garmann D; Buss I; Jaehde U
    Chemotherapy; 2010; 56(1):1-8. PubMed ID: 20185910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells.
    Poulain L; Sichel F; Crouet H; Bureau F; Gauduchon P; Gignoux M; Le Talaër JY
    Cancer Chemother Pharmacol; 1997; 40(5):385-90. PubMed ID: 9272114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models.
    Ohta T; Ohmichi M; Hayasaka T; Mabuchi S; Saitoh M; Kawagoe J; Takahashi K; Igarashi H; Du B; Doshida M; Mirei IG; Motoyama T; Tasaka K; Kurachi H
    Endocrinology; 2006 Apr; 147(4):1761-9. PubMed ID: 16396982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
    Neubauer H; Stefanova M; Solomayer E; Meisner C; Zwirner M; Wallwiener D; Fehm T
    Anticancer Res; 2008; 28(2A):949-55. PubMed ID: 18507041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
    Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
    Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychomotor stimulant effects of methylxanthines in squirrel monkeys: relation to adenosine antagonism.
    Spealman RD
    Psychopharmacology (Berl); 1988; 95(1):19-24. PubMed ID: 3133696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin.
    Yu R; Jin H; Jin C; Huang X; Lin J; Teng Y
    Cell Biochem Funct; 2018 Mar; 36(2):80-87. PubMed ID: 29372560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
    Qian XL; Peng ZL; Liu SL
    Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Xiao F; Li Y; Wan Y; Xue M
    Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
    Shi W; Gu M; Liang L
    Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
    Yu T; Yang Y; Zhang J; He H; Ren X
    Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.